Evidence map›Paper›PMID 40934761›Full record

ArticleRespiratory investigation2025

Impact of medications on lung function in fibrotic hypersensitivity pneumonitis.

Takemoto Abe, Tsukasa Okamoto, Takashi Shimamura, Masaru Ejima, Shiro Sonoda, Tsuyoshi Shirai, Masahiro Ishizuka, Haruhiko Furusawa, Tomoya Tateishi, Ryoichi Hanazawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Respiratory investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takemoto AbeDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Tsukasa OkamotoDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan; Center for Personalized Medicine for Healthy Aging, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. Electronic address: tokamoto.pulm@tmd.ac.jp.
Takashi ShimamuraDepartment of Respiratory Medicine, Yokohama City Minato Red Cross Hospital, 3-12-1 Shinyamashita, Naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Masaru EjimaDepartment of Respiratory Medicine, Yokohama City Minato Red Cross Hospital, 3-12-1 Shinyamashita, Naka-ku, Yokohama, Kanagawa Prefecture, Japan.
Shiro SonodaDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Tsuyoshi ShiraiDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Masahiro IshizukaDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Haruhiko FurusawaDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Tomoya TateishiDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Ryoichi HanazawaDepartment of Clinical Biostatistics, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Akihiro HirakawaDepartment of Clinical Biostatistics, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Yasunari MiyazakiDepartment of Respiratory Medicine, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypersensitivity pneumonitis (HP) is primarily managed through antigen avoidance. However, symptoms often persist even after avoidance, necessitating systemic therapies such as glucocorticoids, immunosuppressants, and antifibrotic agents. The impact of these medications on pulmonary function remains uncertain. To clarify the effects of these systemic therapies on lung function in fibrotic HP, we conducted a retrospective cohort study analyzing longitudinal pulmonary function data.

methodsPatients were identified at our center. Changes in lung function before and after treatment initiation were analyzed using linear mixed effects model and interrupted time series analysis. Multivariate analysis adjusted for age, sex, and smoking history.

resultsA total of 388 patients were included. Multivariate regression analysis revealed an annual decline in forced vital capacity (FVC) percent predicted of 3.16 % (95 % confidence interval: 2.73-3.58). Untreated patients had a slower decline (1.68 % per year, 95 % confidence interval: 0.83-2.52), while treated patients showed a reduction in annual decline from 6.96 % (95 % confidence interval: 6.27-7.65) before treatment to 3.03 % thereafter (P < 0.001). Glucocorticoids alone reduced the decline from 6.96 % (95 % confidence interval: 5.57-8.34) to 0.32 % per year (P < 0.001), while antifibrotic agents slowed it from 4.24 % (95 % confidence interval: 3.09-5.40) to 1.24 % per year (P < 0.001).

conclusionSystemic therapies, particularly glucocorticoids and antifibrotic agents, significantly slow the decline in FVC percent predicted in patients with fibrotic HP. Prospective trials are needed to confirm these findings.

Indexed as

Alveolitis, Extrinsic AllergicAntifibrotic AgentsGlucocorticoidsImmunosuppressive AgentsLungPulmonary FibrosisAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedRespiratory Function TestsRetrospective StudiesVital CapacityAntifibrotic AgentsGlucocorticoidsImmunosuppressive AgentsAntifibrotic agentsGlucocorticoidsImmunoregulationPulmonary fibrosisPulmonary function tests

Identifiers

PMID40934761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.